Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study. (PubMed, Ther Adv Gastroenterol) - Sep 13, 2026 - "While 57.4% of patients did not experience any adverse event within 24 weeks, the two most frequent adverse events were mild application-site pain (19.0%) and localized erythema (20.7%) with no need for risankizumab discontinuation. OBI-risankizumab therapy is highly accepted and could be the most preferred maintenance regimen in patients with CD."
Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Pain
|
|
Anthony Buisson; Antoine Blain; Bénédicte Caron; Bruno Pereira; Cyrielle Gilletta de Saint Joseph; David Laharie; Gilles Boschetti; Guillaume Le Cosquer; Hedia Brixi; Karim Gebara; Laurent Peyrin-Biroulet; Lucine Vuitton; Ludovic Caillo; Maria Nachury; Mathurin Fumery; Mélanie Serrero; Pascal Juillerat; Romain Altwegg; Xavier Hébuterne
|